Webinar: Phenotypic assays for CNS disease drug discovery
Supported by:
21 September 2017
Central nervous system (CNS) disorders constitute a growing unmet medical need, with increasing prevalence of aging-related diseases (Alzheimer’s and Parkinson’s). While classical approaches in cell lines and primary neurons are valuable, (patient-derived) stem cell-based neuronal model systems are rapidly developing into established screening tools.
In this webinar, we highlight in vitro models and phenotypic assays to discover and validate novel targets and promising lead molecules.
The rest of this content is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here
Related topics
Assays, Drug Discovery Processes, Target Validation, Translational Science
Related organisations
Charles River Laboratories
